Company performance
Add to research
Current Price
as of Jun 13, 2025$0.41
P/E Ratio
N/A
Market Cap
$23.69M
Description
Add to research
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerBCAB
- Price$0.4055-5.32%
Trading Information
- Market cap$23.69M
- Float76.30%
- Average Daily Volume (1m)546,003
- Average Daily Volume (3m)547,258
- EPS-$1.22
Company
- Revenue$11.00M
- Rev growth (1yr)N/A
- Net income-$15.33M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$17.43M
- EV-$11.61M
- EV/Revenue-1.06
- P/EN/A
- P/S2.15
- P/B43.28
- Debt/Equity101.28
Documents
Add to research
SEC Filings
Factset Street Account
Earnings Calls
Factset